Chronic Myeloid Leukemia
CHRONIC MYELOID LEUKEMIA ADVISOR
FEATURED CONTENT
-
Data suggest that most patients who use medical aid in dying (MAID) have cancer, but some oncology providers do not feel well informed about MAID.
-
New data highlight the high cost of targeted oral anticancer medicines for patients with Medicare Part D coverage.
-
The likelihood of recovery of major molecular response after resuming TKI therapy at reduced doses was 86%.
-
“Excellent” overall survival is achievable with currently available drugs, according to researchers.
-
The FDA tends to approve cancer drugs faster than other agencies, but there is no link between faster review and high clinical benefit.
CHRONIC MYELOID LEUKEMIA NEWS
Next post in Chronic Myeloid Leukemia
Loading...
Loading...